Tempest Therapeutics, Inc. (OVAS) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Revenue growth							-100.0%	-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross margin
Selling, general and administrative [+]	3.1	2.9	3.1	2.8	3.1	3.1	2.6	3.1
General and administrative	3.1	2.9	3.1	2.8	3.1	3.1	2.6	3.1
Research and development	4.4	4.7	5.8	6.0	5.7	5.1	4.7	4.6
Equity in earnings
EBITDA [+]	-7.4	-7.5	-8.7	-8.6	-8.7	-8.1	-7.2	-7.6
EBITDA growth	-14.7%	-7.4%	20.5%	12.3%	29.3%	59.5%	-200.3%	-238.3%
EBITDA margin
Depreciation and amortization	0.1	0.1	0.2	0.2	0.1	0.1	0.1	0.1
EBIT [+]	-7.5	-7.6	-8.9	-8.8	-8.8	-8.2	-7.3	-7.7
EBIT growth	-14.9%	-7.1%	21.7%	13.4%	29.3%	59.2%	-202.2%	-242.4%
EBIT margin
Interest expense	0.4	0.3	0.4	0.4	0.5	0.3	0.3	0.4
Interest expense	0.4	0.3	0.4	0.4	0.5	0.3	0.3	0.4
Other income (expense), net [+]	0.2	0.3	0.3	0.2	0.1	0.0	-0.1	0.1
Other	0.2	-0.3			0.1	0.0	0.0
Pre-tax income	-7.6	-7.6	-9.1	-8.9	-9.2	-8.5	-7.8	-8.1
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-7.6	-7.6	-9.1	-8.9	-9.2	-8.5	-7.8	-8.1
Net margin

Basic EPS [+]	($0.54)	($0.55)	($0.79)	($0.66)	($0.79)	($1.18)	($2.05)	($1.21)
Growth	-32.1%	-53.2%	-61.6%	-45.7%	-89.6%	-88.8%	425.8%	-89.2%
Diluted EPS [+]	($0.54)	($0.55)	($0.79)	($0.66)	($0.79)	($1.18)	($2.05)	($1.21)
Growth	-32.1%	-53.2%	-61.6%	-45.7%	-89.6%	-88.8%	425.8%	-89.2%

Shares outstanding (basic) [+]	14.1	13.8	11.5	13.6	11.6	7.2	3.8	6.7
Growth	21.8%	92.0%	204.7%	103.0%	1150.6%	1312.4%	-79.9%	1287.7%
Shares outstanding (diluted) [+]	14.1	13.8	11.5	13.6	11.6	7.2	3.8	6.7
Growth	21.8%	92.0%	204.7%	103.0%	1150.6%	1312.4%	-79.9%	1287.7%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.